Francois Benard

List of Publications by Year
in descending order

247 papers	7,861 citations	50276 46 h-index	74163 75 g-index
259 all docs	259 docs citations	259 times ranked	7047 citing authors

#	Article	IF	Citations
1	A Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptorâ€“Positive Prostate Cancer. Journal of Nuclear Medicine, 2022, 63, 424-430.	5.0	12
2	Synthesis and preliminary evaluation of octreotate conjugates of bioactive synthetic amatoxins for targeting somatostatin receptor (sstr2) expressing cells. RSC Chemical Biology, 2022, 3, 69-78.	4.1	7
3	Clinical Applications of Artificial Intelligence in Positron Emission Tomography of Lung Cancer. PET Clinics, 2022, 17, 77-84.	3.0	5
4	Radiolabeled Antibodies for Cancer Radioimmunotherapy. , 2022, , 297-345.		0
5	Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands. Clinical Cancer Research, 2022, 28, 1628-1639.	7.0	6
6	Quantitative evaluation of PSMA PET imaging using a realistic anthropomorphic phantom and shell-less radioactive epoxy lesions. EJNMMI Physics, 2022, 9, 2.	2.7	2
7	Patterns of Prostate Cancer Recurrence After Brachytherapy Determined by Prostate-Specific Membrane Antigenâ€“Positron Emission Tomography and Computed Tomography Imaging. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1126-1134.	0.8	5
8	[²¹³Bi]Bi³⁺/[¹¹¹In]In³⁺-neunpa-cycMSH: Theranostic Radiopharmaceutical Targeting Melanomaâ€€Structural, Radiochemical, and Biological Evaluation. Bioconjugate Chemistry, 2022, 33, 505-522.	3.6	3
9	PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial. BMC Cancer, 2022, 22, 251.	2.6	5
10	Development of a multi faceted platform containing a tetrazine, fluorophore and chelator: synthesis, characterization, radiolabeling, and immuno-SPECT imaging. EJNMMI Radiopharmacy and Chemistry, 2022, 7, .	3.9	2
11	Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation. Nature Chemical Biology, 2022, 18, 963-971.	8.0	83
12	68Ga-Labeled [Leu13ΨThz14]Bombesin(7â€“14) Derivatives: Promising GRPR-Targeting PET Tracers with Low Pancreas Uptake. Molecules, 2022, 27, 3777.	3.8	6
13	Trastuzumab-conjugated oxine-based ligand for [89Zr]Zr4+ immunoPET. Journal of Inorganic Biochemistry, 2022, , 111936.	3.5	3
14	²²⁵Ac-H₄py4pa for Targeted Alpha Therapy. Bioconjugate Chemistry, 2021, 32, 1348-1363.	3.6	42
15	The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study. Journal of Nuclear Medicine, 2021, 62, 81-87.	5.0	25
16	Machine Learning in Nuclear Medicine: Part 2â€”Neural Networks and Clinical Aspects. Journal of Nuclear Medicine, 2021, 62, 22-29.	5.0	13
17	High-Contrast CXCR4-Targeted ¹⁸F-PET Imaging Using a Potent and Selective Antagonist. Molecular Pharmaceutics, 2021, 18, 187-197.	4.6	16
18	Development and biological evaluation of[18F]FMN3PA & [18F]FMN3PU for leucine-rich repeat kinase 2 (LRRK2) inÂvivo PET imaging. European Journal of Medicinal Chemistry, 2021, 211, 113005.	5.5	8

#	Article	IF	Citations
19	¹⁷⁷Lu-Labeled Albumin-Binderâ€“Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio. Journal of Nuclear Medicine, 2021, 62, 521-527.	5.0	40
20	Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood, 2021, 137, 929-938.	1.4	57
21	Synthesis of DOTA-pyridine chelates for 64Cu coordination and radiolabeling of Î±MSH peptide. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 3.	3.9	10
22	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigenâ€“Targeted ¹⁸F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. Journal of Nuclear Medicine, 2021, 62, 1430-1437.	5.0	24
23	Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. Blood Advances, 2021, 5, 3647-3655.	5.2	4
24	Evaluation of ¹⁸F-EF5 for detection of hypoxia in localized adenocarcinoma of the prostate. Acta OncolÃ³gica, 2021, 60, 1489-1498.	1.8	2
25	Isolation and characterization of monoclonal antibodies against human carbonic anhydrase-IX. MAbs, 2021, 13, 1999194.	5.2	5
26	Comparison of biological properties of [¹⁷⁷Lu]Luâ€ProBOMB1 and [¹⁷⁷Lu]Luâ€NeoBOMB1 for GRPR targeting. Journal of Labelled Compounds and Radiopharmaceuticals, 2020, 63, 56-64.	1.0	7
27	Toward ¹⁸Fâ€Labeled Theranostics: A Single Agent that Can Be Labeled with ¹⁸F, ⁶⁴Cu, or ¹⁷⁷Lu. ChemBioChem, 2020, 21, 943-947.	2.6	16
28	The Effect of Chirality on the Application of 5-[18F]Fluoro-Aminosuberic Acid ([18F]FASu) for Oxidative Stress Imaging. Molecular Imaging and Biology, 2020, 22, 873-882.	2.6	5
29	Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation. Cancer Letters, 2020, 493, 31-40.	7.2	12
30	Evaluation of Met-Val-Lys as a Renal Brush Border Enzyme-Cleavable Linker to Reduce Kidney Uptake of 68Ga-Labeled DOTA-Conjugated Peptides and Peptidomimetics. Molecules, 2020, 25, 3854.	3.8	18
31	A Systematic Review of Molecular Imaging Agents Targeting Bradykinin B1 and B2 Receptors. Pharmaceuticals, 2020, 13, 199.	3.8	25
32	Selective Cyclized Î±-Melanocyte-Stimulating Hormone Derivative with Multiple N-Methylations for Melanoma Imaging with Positron Emission Tomography. ACS Omega, 2020, 5, 10767-10773.	3.5	8
33	Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. Blood, 2020, 136, 2803-2811.	1.4	46
34	Synthesis and Evaluation of a Macrocyclic Actiniumâ€225 Chelator, Quality Control and In Vivo Evaluation of ²²⁵Acâ€crownâ€Î±MSH Peptide. Chemistry - A European Journal, 2020, 26, 11435-11440.	3.3	41
35	[^{nat/44}Sc(pypa)]^{â^'}: Thermodynamic Stability, Radiolabeling, and Biodistribution of a Prostate-Specific-Membrane-Antigen-Targeting Conjugate. Inorganic Chemistry, 2020, 59, 1985-1995.	4.0	23
36	Synthesis and 18F-radiolabeling of thymidine AMBF3 conjugates. RSC Medicinal Chemistry, 2020, 11, 569-576.	3.9	4

#	Article	IF	Citations
37	Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer. Canadian Urological Association Journal, 2020, 15, 162-172.	0.6	12
38	Impact of image reconstruction method on dose distributions derived from ⁹⁰Y PET images: phantom and liver radioembolization patient studies. Physics in Medicine and Biology, 2020, 65, 215022.	3.0	7
39	Pharmacokinetics, radiation dosimetry, acute toxicity and automated synthesis of [18F]AmBF3-TATE. EJNMMI Research, 2020, 10, 25.	2.5	10
40	Insight into the Development of PET Radiopharmaceuticals for Oncology. Cancers, 2020, 12, 1312.	3.7	46
41	^tBu₄octapa-alkyl-NHS for metalloradiopeptide preparation. Dalton Transactions, 2020, 49, 7605-7619.	3.3	6
42	Electrostatic Effects Accelerate Decatungstate-Catalyzed Câ€“H Fluorination Using [¹⁸F]- and [¹⁹F]NFSI in Small Molecules and Peptide Mimics. ACS Catalysis, 2019, 9, 8276-8284.	11.2	29
43	Cyclotron-based production of Tc-99m and other metals. Nuclear Medicine and Biology, 2019, 72-73, S6-S7.	0.6	0
44	Fluorescent Isoindole Crosslink (FlICk) Chemistry: A Rapid, Userâ€friendly Stapling Reaction. Angewandte Chemie, 2019, 131, 14258-14262.	2.0	17
45	InnenrÃ¼cktitelbild: Fluorescent Isoindole Crosslink (FlICk) Chemistry: A Rapid, Userâ€friendly Stapling Reaction (Angew. Chem. 40/2019). Angewandte Chemie, 2019, 131, 14527-14527.	2.0	0
46	Evaluation of the Tetrakis(3-Hydroxy-4-Pyridinone) Ligand THPN with Zirconium(IV): Thermodynamic Solution Studies, Bifunctionalization, and in Vivo Assessment of Macromolecular 89Zr-THPN-Conjugates. Inorganic Chemistry, 2019, 58, 14667-14681.	4.0	13
47	Evaluation of polydentate picolinic acid chelating ligands and an Î±-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced 225Ac. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 21.	3.9	35
48	Patterns of Prostate Cancer Recurrence after Brachytherapy Imaged with PSMA-Targeting 18F-Dcfpyl PET/CT. International Journal of Radiation Oncology Biology Physics, 2019, 105, E304-E305.	0.8	2
49	18F-Labeled Cyclized Î±-Melanocyte-Stimulating Hormone Derivatives for Imaging Human Melanoma Xenograft with Positron Emission Tomography. Scientific Reports, 2019, 9, 13575.	3.3	12
50	[⁶⁸Ga]Ga/[¹⁷⁷Lu]Lu-BL01, a Novel Theranostic Pair for Targeting C-X-C Chemokine Receptor 4. Molecular Pharmaceutics, 2019, 16, 4688-4695.	4.6	15
51	Analysis of radioactive waste generated during the cyclotron production of 99mTc. Physics in Medicine and Biology, 2019, 64, 055008.	3.0	2
52	¹⁸F-Branched-Chain Amino Acids: Structureâ€“Activity Relationships and PET Imaging Potential. Journal of Nuclear Medicine, 2019, 60, 1003-1009.	5.0	12
53	Positron Emission Tomography Imaging of the Gastrin-Releasing Peptide Receptor with a Novel Bombesin Analogue. ACS Omega, 2019, 4, 1470-1478.	3.5	23
54	Fluorescent Isoindole Crosslink (FlICk) Chemistry: A Rapid, Userâ€friendly Stapling Reaction. Angewandte Chemie - International Edition, 2019, 58, 14120-14124.	13.8	47

#	Article	IF	Citations
55	Functionally Versatile and Highly Stable Chelator for ¹¹¹In and ¹⁷⁷Lu: Proof-of-Principle Prostate-Specific Membrane Antigen Targeting. Bioconjugate Chemistry, 2019, 30, 1539-1553.	3.6	40
56	A Prospective Study on ¹⁸F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1587-1593.	5.0	84
57	A Metal-Free DOTA-Conjugated ¹⁸F-Labeled Radiotracer: [¹⁸F]DOTA-AMBF₃-LLP2A for Imaging VLA-4 Over-Expression in Murine Melanoma with Improved Tumor Uptake and Greatly Enhanced Renal Clearance. Bioconjugate Chemistry, 2019, 30, 1210-1219.	3.6	22
58	Non-invasive Use of Positron Emission Tomography to Monitor Diethyl maleate and Radiation-Induced Changes in System xCâ^' Activity in Breast Cancer. Molecular Imaging and Biology, 2019, 21, 1107-1116.	2.6	4
59	Machine Learning in Nuclear Medicine: Part 1â€"Introduction. Journal of Nuclear Medicine, 2019, 60, 451-458.	5.0	47
60	One-Step ¹⁸F-Labeling and Preclinical Evaluation of Prostate-Specific Membrane Antigen Trifluoroborate Probes for Cancer Imaging. Journal of Nuclear Medicine, 2019, 60, 1160-1166.	5.0	17
61	Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Therapies. Bioconjugate Chemistry, 2019, 30, 487-502.	3.6	73
62	Organoboronates. , 2019, , 519-549.		0
63	Synthesis and evaluation of bifunctional tetrahydroxamate chelators for labeling antibodies with 89 Zr for imaging with positron emission tomography. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 899-905.	2.2	13
64	Flare on Serial Prostate-Specific Membrane Antigenâ€"Targeted 18F-DCFPyL PET/CT Examinations in Castration-Resistant Prostate Cancer. Clinical Nuclear Medicine, 2018, 43, 213-216.	1.3	14
65	Segmentation-free direct tumor volume and metabolic activity estimation from PET scans. Computerized Medical Imaging and Graphics, 2018, 63, 52-66.	5.8	13
66	Synthesis and evaluation of an ¹⁸Fâ€labeled trifluoroborate derivative of 2â€nitroimidazole for imaging tumor hypoxia with positron emission tomography. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 370-379.	1.0	6
67	Preliminary evaluation of 18F-labeled LLP2A-trifluoroborate conjugates as VLA-4 (Î±4Î²1 integrin) specific radiotracers for PET imaging of melanoma. Nuclear Medicine and Biology, 2018, 61, 11-20.	0.6	11
68	89 Zr for antibody labeling and in vivo studies â€" A comparison between liquid and solid target production. Nuclear Medicine and Biology, 2018, 58, 1-7.	0.6	8
69	18F-DCFPyL PET/CT in Oncocytoma. Clinical Nuclear Medicine, 2018, 43, 921-924.	1.3	7
70	Enhancing Treatment Efficacy of ¹⁷⁷Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies. Molecular Pharmaceutics, 2018, 15, 5183-5191.	4.6	75
71	Siteâ€Selective, Lateâ€Stage Câ^'H ¹⁸Fâ€Fluorination on Unprotected Peptides for Positron Emission Tomography Imaging. Angewandte Chemie, 2018, 130, 12915-12918.	2.0	21
72	Effects of adding an albumin binder chain on [177Lu]Lu-DOTATATE. Nuclear Medicine and Biology, 2018, 66, 10-17.	0.6	23

#	Article	IF	Citations
73	Two bifunctional desferrioxamine chelators for bioorthogonal labeling of biovectors with zirconium-89. Organic and Biomolecular Chemistry, 2018, 16, 5102-5106.	2.8	8
74	Siteâ€Selective, Lateâ€Stage Câ^'H ¹⁸Fâ€Fluorination on Unprotected Peptides for Positron Emission Tomography Imaging. Angewandte Chemie - International Edition, 2018, 57, 12733-12736.	13.8	71
75	Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD. Haematologica, 2018, 103, e590-e593.	3.5	16
76	Melanoma Imaging Using ¹⁸F-Labeled Î±-Melanocyte-Stimulating Hormone Derivatives with Positron Emission Tomography. Molecular Pharmaceutics, 2018, 15, 2116-2122.	4.6	31
77	Monosodium Glutamate Reduces ⁶⁸Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model. Journal of Nuclear Medicine, 2018, 59, 1865-1868.	5.0	49
78	Metformin Discontinuation prior to FDG PET/CT: A Randomized Controlled Study to Compare 24- and 48-hour Bowel Activity. Radiology, 2018, 289, 418-425.	7.3	31
79	Synthesis and evaluation of an 18F-labeled boramino acid analog of aminosuberic acid for PET imaging of the antiporter system xCâ^'. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3579-3584.	2.2	8
80	Effects of Linker Modification on Tumor-to-Kidney Contrast of ⁶⁸Ga-Labeled PSMA-Targeted Imaging Probes. Molecular Pharmaceutics, 2018, 15, 3502-3511.	4.6	45
81	Radiolabeled R954 Derivatives for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography. Molecular Pharmaceutics, 2017, 14, 821-829.	4.6	7
82	Design, synthesis and evaluation of novel bifunctional tetrahydroxamate chelators for PET imaging of 89 Zr-labeled antibodies. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 708-712.	2.2	23
83	2-18F-Fluoroethanol Is a PET Reporter of Solid Tumor Perfusion. Journal of Nuclear Medicine, 2017, 58, 815-820.	5.0	3
84	¹⁸F-Fluorination of Unactivated Câ€"H Bonds in Branched Aliphatic Amino Acids: Direct Synthesis of Oncological Positron Emission Tomography Imaging Agents. Journal of the American Chemical Society, 2017, 139, 3595-3598.	13.7	119
85	Design, synthesis and evaluation of¹⁸F-labeled cationic carbonic anhydrase IX inhibitors for PET imaging. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 722-730.	5.2	42
86	Modeling the pressure rise of a liquid target on a medical cyclotron: Steady-state analysis. Applied Radiation and Isotopes, 2017, 120, 22-29.	1.5	3
87	Synthesis and evaluation of a 68Ga-labeled bradykinin B1 receptor agonist for imaging with positron emission tomography. Bioorganic and Medicinal Chemistry, 2017, 25, 690-696.	3.0	3
88	Synthesis and evaluation of 18 F-labeled CJ-042794 for imaging prostanoid EP4 receptor expression in cancer with positron emission tomography. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2094-2098.	2.2	13
89	Radionuclidic purity measurements for cyclotron-produced 99mTc via 100Mo(p,2n) at 18â€...MeV. AIP Conference Proceedings, 2017, , .	0.4	0
90	p-NO₂â€"Bnâ€"H₄neunpa and H₄neunpaâ€"Trastuzumab: Bifunctional Chelator for Radiometalpharmaceuticals and ¹¹¹In Immuno-Single Photon Emission Computed Tomography Imaging. Bioconjugate Chemistry, 2017, 28, 2145-2159.	3.6	37

#	Article	IF	Citations
91	Addressing Chirality in the Structure and Synthesis of [¹⁸F]5â€Fluoroaminosuberic Acid ([¹⁸F]FASu). Chemistry - A European Journal, 2017, 23, 11100-11107.	3.3	6
92	Molecular Imaging and Radionuclide Therapy of Melanoma Targeting the Melanocortin 1 Receptor. Molecular Imaging, 2017, 16, 153601211773791.	1.4	14
93	FDG PET and FES PET Predict PFS on Endocrine Therapyâ€"Letter. Clinical Cancer Research, 2017, 23, 3474-3474.	7.0	0
94	Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography. EJNMMI Radiopharmacy and Chemistry, 2017, 2, 4.	3.9	22
95	¹⁸F-5-Fluoroaminosuberic Acid as a Potential Tracer to Gauge Oxidative Stress in Breast Cancer Models. Journal of Nuclear Medicine, 2017, 58, 367-373.	5.0	36
96	Medical Isotope Production at TRIUMF â€“ from Imaging to Treatment. Physics Procedia, 2017, 90, 200-208.	1.2	38
97	Preclinical Melanoma Imaging with ⁶⁸Ga-Labeled Î±-Melanocyte-Stimulating Hormone Derivatives Using PET. Theranostics, 2017, 7, 805-813.	10.0	37
98	Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX. Theranostics, 2017, 7, 4322-4339.	10.0	59
99	Improving the stability of 11Câ€“labeled L-methionine with ascorbate. EJNMMI Radiopharmacy and Chemistry, 2017, 2, 13.	3.9	7
100	Imaging study of using radiopharmaceuticals labeled with cyclotron-produced99mTc. Physics in Medicine and Biology, 2016, 61, 8199-8213.	3.0	9
101	Automated synthesis of [18F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models. EJNMMI Research, 2016, 6, 40.	2.5	71
102	One-step synthesis of 4-[¹⁸F]fluorobenzyltriphenylphosphonium cation for imaging with positron emission tomography. Journal of Labelled Compounds and Radiopharmaceuticals, 2016, 59, 467-471.	1.0	18
103	Long-Term Follow-Up of Outcomes With F-18-Fluorodeoxyglucose Positron Emission Tomography Imagingâ€"Assisted Management of Patients With Severe Left Ventricular Dysfunction Secondary to Coronary Disease. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	60
104	Targeting the Neuropeptide Y1 Receptor for Cancer Imaging by Positron Emission Tomography Using Novel Truncated Peptides. Molecular Pharmaceutics, 2016, 13, 3657-3664.	4.6	15
105	Design, synthesis and evaluation of 18F-labeled bradykinin B1 receptor-targeting small molecules for PET imaging. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4095-4100.	2.2	6
106	Tumor Lesion Segmentation from 3D PET Using a Machine Learning Driven Active Surface. Lecture Notes in Computer Science, 2016, , 271-278.	1.3	2
107	PET Metabolic Biomarkers for Cancer. Biomarkers in Cancer, 2016, 8s2, BIC.S27483.	3.6	17
108	Radiolabeled B9958 Derivatives for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography: Effect of the Radiolabelâ€"Chelator Complex on Biodistribution and Tumor Uptake. Molecular Pharmaceutics, 2016, 13, 2823-2832.	4.6	14

#	Article	IF	Citations
109	Synthesis and evaluation of 18 F-labeled 4-nitrobenzyl derivatives for imaging tumor hypoxia with positron emission tomography: Comparison of 2-[18 F]fluoroethyl carbonate and 2-[18 F]fluoroethyl carbamate. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 584-588.	2.2	3
110	Molybdenum target specifications for cyclotron production of^{99m}Tc based on patient dose estimates. Physics in Medicine and Biology, 2016, 61, 542-553.	3.0	15
111	PET Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with ⁶⁸Ga-Labeled Benzenesulfonamides. Molecular Pharmaceutics, 2016, 13, 1137-1146.	4.6	49
112	Synthesis and evaluation of 18F-trifluoroborate derivatives of triphenylphosphonium for myocardial perfusion imaging. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1675-1679.	2.2	12
113	An analytical approach of thermodynamic behavior in a gas target system on a medical cyclotron. Applied Radiation and Isotopes, 2016, 107, 252-258.	1.5	12
114	18F-AmBF3-MJ9: A novel radiofluorinated bombesin derivative for prostate cancer imaging. Bioorganic and Medicinal Chemistry, 2015, 23, 1500-1506.	3.0	51
115	¹⁸F-Trifluoroborate Derivatives of [Des-Arg¹⁰]Kallidin for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography. Molecular Pharmaceutics, 2015, 12, 974-982.	4.6	38
116	Comparative Studies of Three ⁶⁸Ga-Labeled [Des-Arg¹⁰]Kallidin Derivatives for Imaging Bradykinin B1 Receptor Expression with PET. Journal of Nuclear Medicine, 2015, 56, 622-627.	5.0	17
117	Trimeric Radiofluorinated Sulfonamide Derivatives to Achieve In Vivo Selectivity for Carbonic Anhydrase IXâ€“Targeted PET Imaging. Journal of Nuclear Medicine, 2015, 56, 1434-1440.	5.0	48
118	Direct Production of 99mTc via 100Mo(p,2n) on Small Medical Cyclotrons. Physics Procedia, 2015, 66, 383-395.	1.2	46
119	Production of Y-86 and other radiometals for research purposes using a solution target system. Nuclear Medicine and Biology, 2015, 42, 842-849.	0.6	42
120	Quantitative analysis of relationships between irradiation parameters and the reproducibility of cyclotron-produced99mTc yields. Physics in Medicine and Biology, 2015, 60, 3883-3903.	3.0	4
121	Imaging Bradykinin B1 Receptor with ⁶⁸Ga-Labeled [des-Arg¹⁰]Kallidin Derivatives: Effect of the Linker on Biodistribution and Tumor Uptake. Molecular Pharmaceutics, 2015, 12, 2879-2888.	4.6	20
122	16Î±-[18F]-fluoro-17ÃŸ-oestradiol ([18F]FES): A biomarker for imaging oestrogen receptor expression with positron emission tomography (PET). Medecine Nucleaire, 2015, 39, 64-70.	0.2	3
123	A multicentre comparison of quantitative 90Y PET/CT for dosimetric purposes after radioembolization with resin microspheres. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1202-1222.	6.4	131
124	One-step 18F labeling of biomolecules using organotrifluoroborates. Nature Protocols, 2015, 10, 1423-1432.	12.0	76
125	A fast and simple dose-calibrator-based quality control test for the radionuclidic purity of cyclotron-produced^{99m}Tc. Physics in Medicine and Biology, 2015, 60, 8229-8247.	3.0	7
126	In Vivo Radioimaging of Bradykinin Receptor B1, a Widely Overexpressed Molecule in Human Cancer. Cancer Research, 2015, 75, 387-393.	0.9	48

#	Article	IF	Citations
127	Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation. Blood, 2015, 126, 579-579.	1.4	20
128	Synthesis and evaluation of ¹⁸F-labeled carbonic anhydrase IX inhibitors for imaging with positron emission tomography. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 249-255.	5.2	63
129	44gSc production using a water target on a 13MeV cyclotron. Nuclear Medicine and Biology, 2014, 41, 401-406.	0.6	52
130	Solid targets for 99mTc production on medical cyclotrons. Journal of Radioanalytical and Nuclear Chemistry, 2014, 299, 1007-1011.	1.5	19
131	A simple route to [11C]N-Me labeling of aminosuberic acid for proof of feasibility imaging of the xCâ˜ transporter. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5512-5515.	2.2	2
132	Cross-Linked Polyethylene Glycol Beads to Separate ^{99m}Tc-Pertechnetate from Low-Specific-Activity Molybdenum. Journal of Nuclear Medicine, 2014, 55, 1910-1914.	5.0	18
133	A new18F-heteroaryltrifluoroborate radio-prosthetic with greatly enhanced stability that is labelled by18Fâ€“19F-isotope exchange in good yield at high specific activity. MedChemComm, 2014, 5, 171-179.	3.4	29
134	An Organotrifluoroborate for Broadly Applicable Oneâ€Step ¹⁸Fâ€Labeling. Angewandte Chemie - International Edition, 2014, 53, 11876-11880.	13.8	139
135	Preclinical Evaluation of a High-Affinity ¹⁸F-Trifluoroborate Octreotate Derivative for Somatostatin Receptor Imaging. Journal of Nuclear Medicine, 2014, 55, 1499-1505.	5.0	77
136	[11C]-Acetoacetate PET imaging: a potential early marker for cardiac heart failure. Nuclear Medicine and Biology, 2014, 41, 863-870.	0.6	22
137	Graphical user interface for yield and dose estimations for cyclotron-produced technetium. Physics in Medicine and Biology, 2014, 59, 3337-3352.	3.0	4
138	Implementation of Multi-Curie Production of ^{99m}Tc by Conventional Medical Cyclotrons. Journal of Nuclear Medicine, 2014, 55, 1017-1022.	5.0	82
139	LONG TERM FOLLOW UP OF OUTCOMES WITH F-18-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IMAGING- ASSISTED MANAGEMENT OF PATIENTS WITH SEVERE LEFT VENTRICULAR DYSFUNCTION SECONDARY TO CORONARY DISEASE: 5-YEAR FOLLOW-UP OF THE PARR-2 RANDOMIZED CONTROLLED TRIAL. Canadian Journal of Cardiology, 2014, 30, S266.	1.7	1
140	Synthesis and evaluation of 18F-labeled tertiary benzenesulfonamides for imaging carbonic anhydrase IX expression in tumours with positron emission tomography. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3064-3068.	2.2	24
141	Phase 2 Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC). Blood, 2014, 124, 392-392.	1.4	23
142	Assessment of the Novel Estrogen Receptor PET Tracer 4-Fluoro-11Î²-methoxy-16Îą-[18F]fluoroestradiol (4FMFES) by PET Imaging in a Breast Cancer Murine Model. Molecular Imaging and Biology, 2013, 15, 625-632.	2.6	18
143	2-[18F]Fluoroethanol and 3-[18F]fluoropropanol: facile preparation, biodistribution in mice, and their application as nucleophiles in the synthesis of [18F]fluoroalkyl aryl ester and ether PET tracers. Nuclear Medicine and Biology, 2013, 40, 850-857.	0.6	23
144	High-Grade Glioma Radiation Therapy Target Volumes and Patterns of Failure Obtained From Magnetic Resonance Imaging and 18F-FDOPA Positron Emission Tomography Delineations From Multiple Observers. International Journal of Radiation Oncology Biology Physics, 2013, 87, 1100-1106.	0.8	37

#	Article	IF	Citations
145	2-Fluoropyridine prosthetic compounds for the 18F labeling of bombesin analogues. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3920-3926.	2.2	14
146	Graphical user interface for yield and doses estimations for cyclotron technetium production. , 2013, , .		0
147	TH-C-141-06: Estimating Cell Density Using Fractional Anisotropy From Postoperative Diffusion Tensor Imaging of High-Grade Gliomas. Medical Physics, 2013, 40, 540-540.	3.0	0
148	(18)F-click labeling of a bombesin antagonist with an alkyne-(18)F-ArBF(3) (-): in vivo PET imaging of tumors expressing the GRP-receptor. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 57-70.	1.0	18
149	Producing radiometals in liquid targets: Proof of feasibility with [sup 94m]Tc. , 2012, , .		4
150	[18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERÎ±-knockdown breast tumors in mice. Nuclear Medicine and Biology, 2012, 39, 57-64.	0.6	17
151	[11C]Acetate restâ€“stress protocol to assess myocardial perfusion and oxygen consumption reserve in a model of congestive heart failure in rats. Nuclear Medicine and Biology, 2012, 39, 287-294.	0.6	29
152	An automated module for the separation and purification of cyclotron-produced 99mTcO4â¯. Nuclear Medicine and Biology, 2012, 39, 551-559.	0.6	53
153	Does FDG PET-Assisted Management of Patients With Left Ventricular Dysfunction Improve Quality of Life? A Substudy of the PARR-2 Trial. Canadian Journal of Cardiology, 2012, 28, 54-61.	1.7	17
154	A new transfer system for solid targets. , 2012, , .		2
155	Theoretical dosimetry estimations for radioisotopes produced by proton-induced reactions on natural and enriched molybdenum targets. Physics in Medicine and Biology, 2012, 57, 1499-1515.	3.0	26
156	Radiometals from liquid targets: 94mTc production using a standard water target on a 13MeV cyclotron. Applied Radiation and Isotopes, 2012, 70, 2308-2312.	1.5	25
157	Comparison of High-grade Glioma Relapses With Radiation Therapy Target Volumes Obtained From MRI and 18 F-FDOPA PET. International Journal of Radiation Oncology Biology Physics, 2012, 84, S270-S271.	0.8	0
158	Quantitative hormone therapy follow-up in an ER+/ERÎ±KD mouse tumor model using FDG and [11C]-methionine PET imaging. EJNMMI Research, 2012, 2, 61.	2.5	8
159	Novel Radiolabeled Peptides for Breast and Prostate Tumor PET Imaging: ⁶⁴Cu/and ⁶⁸Ga/NOTA-PEG-[<scp>d</scp>-Tyr⁶,Î²Ala¹¹,Thi¹³,Nle¹⁴]BBN(6â€¦ Bioconjugate Chemistry, 2012, 23, 1687-1693.	3.6	82
160	The deposition of smooth metallic molybdenum from aqueous electrolytes containing molybdate ions. Electrochemistry Communications, 2012, 15, 78-80.	4.7	50
161	Comparative study of 64Cu/NOTA-[D-Tyr6,Î²Ala11,Thi13,Nle14]BBN(6-14) monomer and dimers for prostate cancer PET imaging. EJNMMI Research, 2012, 2, 8.	2.5	27
162	Evaluation of ⁶⁴Cu-Labeled Bifunctional Chelateâ€“Bombesin Conjugates. Bioconjugate Chemistry, 2011, 22, 1729-1735.	3.6	77

#	Article	IF	Citations
163	Theoretical modeling of yields for proton-induced reactions on natural and enriched molybdenum targets. Physics in Medicine and Biology, 2011, 56, 5469-5484.	3.0	46
164	577 The role of fluorodeoxyglucose positron emission tomography guided management in improving quality of life amongst patients with ischemic left ventricular dysfunction. Canadian Journal of Cardiology, 2011, 27, S269-S270.	1.7	0
165	Cyclotron production of 99mTc: Experimental measurement of the 100Mo(p,x)99Mo, 99mTc and 99gTc excitation functions from 8 to 18 MeV. Nuclear Medicine and Biology, 2011, 38, 907-916.	0.6	106
166	Liquid Xenon Detectors for Positron Emission Tomography. Journal of Physics: Conference Series, 2011, 312, 062006.	0.4	1
167	Impact of Time-of-Flight PET on Whole-Body Oncologic Studies: A Human Observer Lesion Detection and Localization Study. Journal of Nuclear Medicine, 2011, 52, 712-719.	5.0	94
168	The use of FDG-PET to guide consolidative radiotherapy in patients with advanced-stage Hodgkin lymphoma with residual abnormalities on CT scan following ABVD chemotherapy.. Journal of Clinical Oncology, 2011, 29, 8034-8034.	1.6	17
169	MO-F-110-08: Yields and Dosimetry Estimates for Radioisotopes Produced in Proton-Induced Reactions on Enriched Molybdenum Targets. Medical Physics, 2011, 38, 3729-3729.	3.0	0
170	WE-G-214-08: Interobserver Volume Variations in the Target Delineation of High-Grade Gliomas Using Magnetic Resonance Imaging and 18F-FDOPA Positron Emission Tomography. Medical Physics, 2011, 38, 3832-3832.	3.0	0
171	La mesure de lâ€™APS demeure essentielle. Canadian Urological Association Journal, 2011, 5, 378-378.	0.6	0
172	Image-derived input function in dynamic human PET/CT: methodology and validation with 11C-acetate and 18F-fluorothioheptadecanoic acid in muscle and 18F-fluorodeoxyglucose in brain. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1539-1550.	6.4	86
173	[Lys(DOTA)4]BVD15, a novel and potent neuropeptide Y analog designed for Y1 receptor-targeted breast tumor imaging. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 950-953.	2.2	36
174	Novel Matrix Metalloproteinase Inhibitor [18F]Marimastat-Aryltrifluoroborate as a Probe for In vivo Positron Emission Tomography Imaging in Cancer. Cancer Research, 2010, 70, 7562-7569.	0.9	79
175	Impact of F-18 Fluorodeoxyglucose Positron Emission Tomographyâ€“Computed Tomography on Oncologic Patient Management: First 2 Years' Experience at a Single Canadian Cancer Center. Canadian Association of Radiologists Journal, 2010, 61, 13-18.	2.0	4
176	Total Solid-Phase Synthesis of NOTA-Functionalized Peptides for PET Imaging. Organic Letters, 2010, 12, 280-283.	4.6	38
177	FDG-PET Scan Guided Consolidative Radiation Therapy Optimizes Outcome In Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) with Residual Abnormalities on CT Scan Following R-CHOP. Blood, 2010, 116, 854-854.	1.4	9
178	Assessment of Human Biodistribution and Dosimetry of 4-Fluoro-11Î²-Methoxy-16Îą-¹⁸F-Fluoroestradiol Using Serial Whole-Body PET/CT. Journal of Nuclear Medicine, 2009, 50, 100-107.	5.0	36
179	Mechanism of Reduced Myocardial Glucose Utilization During Acute Hypertriglyceridemia in Rats. Molecular Imaging and Biology, 2009, 11, 6-14.	2.6	20
180	Increasing Benefit From Revascularization Is Associated With Increasing Amounts of Myocardial Hibernation. JACC: Cardiovascular Imaging, 2009, 2, 1060-1068.	5.3	159

#	Article	IF	Citations
181	Receptor Imaging in Patients with Breast Cancer. PET Clinics, 2009, 4, 329-341.	3.0	1
182	Primary myxoid sarcoma of the pleura. Canadian Journal of Surgery, 2009, 52, E93-E94.	1.2	1
183	The challenges of improving breast cancer outcome with diagnostic imaging techniques. Oncology, 2009, 23, 264, 266.	0.5	0
184	[11C] Acetoacetate Utilization by Breast and Prostate Tumors: a PET and Biodistribution Study in Mice. Molecular Imaging and Biology, 2008, 10, 217-223.	2.6	23
185	[18F]Fluorinated estradiol derivatives for oestrogen receptor imaging: impact of substituents, formulation and specific activity on the biodistribution in breast tumour-bearing mice. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1473-1479.	6.4	22
186	Automated synthesis of ¹¹Câ€Î²â€hydroxybutyrate by enzymatic conversion of ¹¹Câ€acetoacetate using Î²â€hydroxybutyrate dehydrogenase. Journal of Labelled Compounds and Radiopharmaceuticals, 2008, 51, 242-245.	1.0	7
187	Targeting gastrin-releasing peptide receptors of prostate cancer cells for photodynamic therapy with a phthalocyanineâ€“bombesin conjugate. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2424-2427.	2.2	40
188	Copper-64 labeled sulfophthalocyanines for positron emission tomography (PET) imaging in tumor-bearing rats. Journal of Porphyrins and Phthalocyanines, 2008, 12, 49-53.	0.8	16
189	Release of Markers of Myocardial Damage Evaluated in the Coronary Sinus During Cardiac Surgery. Journal of Investigative Medicine, 2007, 55, 195-201.	1.6	8
190	Effective specific activities determined by scintillation proximity counting for production runs of [18F]FES and 4F-M[18F]FES. Nuclear Medicine and Biology, 2007, 34, 325-329.	0.6	10
191	Automated synthesis of 11Î²-methoxy-4,16Îµ-[16Îµ-18F]difluoroestradiol (4F-M[18F]FES) for estrogen receptor imaging by positron emission tomography. Nuclear Medicine and Biology, 2007, 34, 459-464.	0.6	16
192	Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. European Journal of Cancer, 2007, 43, 536-543.	2.8	77
193	Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening. European Journal of Cancer, 2007, 43, 1180-1187.	2.8	29
194	F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction and Suspected Coronary Disease. Journal of the American College of Cardiology, 2007, 50, 2002-2012.	2.8	403
195	Automated synthesis of 11C-acetoacetic acid, a key alternate brain fuel to glucose. Applied Radiation and Isotopes, 2007, 65, 934-940.	1.5	22
196	Synthesis, characterization, and estrogen receptor binding affinity of flavone-, indole-, and furan-estradiol conjugates. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3212-3216.	2.2	41
197	A Small Animal Positron Emission Tomography Study of the Effect of Chemotherapy and Hormonal Therapy on the Uptake of 2-Deoxy-2-[F-18]fluoro-d-glucose in Murine Models of Breast Cancer. Molecular Imaging and Biology, 2007, 9, 144-150.	2.6	43
198	Steroid Receptor Imaging in Breast Cancer. PET Clinics, 2006, 1, 51-70.	3.0	9

#	Article	IF	Citations
199	Thyroid Cancer Presenting as a PET Incidentaloma in a Patient With Concomitant Breast Cancer Metastases to the Thyroid. Clinical Nuclear Medicine, 2006, 31, 382-385.	1.3	10
200	The Effect of Insulin on the Intracellular Distribution of 14(R,S)-[18F]Fluoro-6-thia-heptadecanoic Acid in Rats. Molecular Imaging and Biology, 2006, 8, 237-244.	2.6	43
201	Optimization of Whole-Body Positron Emission Tomography Imaging by Using Delayed 2-Deoxy-2-[F-18]fluoro-d-glucose Injection Following I.V. Insulin in Diabetic Patients. Molecular Imaging and Biology, 2006, 8, 348-354.	2.6	40
202	Bone marrow hypermetabolism on 18F-FDG PET as a survival prognostic factor in non-small cell lung cancer. Journal of Nuclear Medicine, 2006, 47, 559-65.	5.0	39
203	Fluorine-18â€"Labeled Deoxyglucose Positron Emission Tomography in the Diagnosis and Management of Aortitis With Pulmonary Artery Involvement. Circulation, 2005, 111, e375-6.	1.6	6
204	Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography. Breast Cancer Research, 2005, 7, 153-62.	5.0	77
205	Cardiac PET imaging of blood flow, metabolism, and function in normal and infarcted rats. IEEE Transactions on Nuclear Science, 2004, 51, 696-704.	2.0	17
206	Impact on estrogen receptor binding and target tissue uptake of [18F]fluorine substitution at the 16Î±-position of fulvestrant (faslodex; ICI 182,780). Nuclear Medicine and Biology, 2004, 31, 691-698.	0.6	28
207	Breast cancer models to study the expression of estrogen receptors with small animal PET imaging. Nuclear Medicine and Biology, 2004, 31, 761-770.	0.6	45
208	Respiratory gating for 3-dimensional PET of the thorax: feasibility and initial results. Journal of Nuclear Medicine, 2004, 45, 214-9.	5.0	143
209	Quantitative myocardial perfusion and coronary reserve in rats with 13N-ammonia and small animal PET: impact of anesthesia and pharmacologic stress agents. Journal of Nuclear Medicine, 2004, 45, 1924-30.	5.0	42
210	Evaluation of outcome and cost-effectiveness using an FDG PET-guided approach to management of patients with coronary disease and severe left ventricular dysfunction (PARR-2): rationale, design, and methods. Contemporary Clinical Trials, 2003, 24, 776-794.	1.9	22
211	Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Seminars in Nuclear Medicine, 2003, 33, 148-162.	4.6	159
212	Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. Journal of Nuclear Medicine, 2003, 44, 1225-31.	5.0	74
213	Quantitative gated PET for the assessment of left ventricular function in small animals. Journal of Nuclear Medicine, 2003, 44, 1655-61.	5.0	50
214	Cardiac studies in rats with /sup 11/C-acetate and PET: a comparison with /sup 13/N-ammonia. IEEE Transactions on Nuclear Science, 2002, 49, 2322-2327.	2.0	21
215	Synthesis of 16Î±-fluoro ICI 182,780 derivatives: powerful antiestrogens to image estrogen receptor densities in breast cancer by positron emission tomography. Journal of the Chemical Society, Perkin Transactions 1, 2002, , 2275-2281.	1.3	16
216	18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids, 2002, 67, 765-775.	1.8	68

#	Article	IF	Citations
217	Whole-body FDG-PET imaging in the management of patients with cancer. Seminars in Nuclear Medicine, 2002, 32, 35-46.	4.6	178
218	Superiority of Iodine-123 Compared with Iodine-131 Scanning for Thyroid Remnants in Patients with Differentiated Thyroid Cancer. Clinical Nuclear Medicine, 2001, 26, 6-9.	1.3	109
219	Synthesis of 2, 16Î±â€•and 4, 16Î±â€[16Î±â€¹⁸F]difluoroestradiols and their 11Î²â€methoxy derivatives for estrogen receptor imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, S348.	1.0	3
220	Extensive F-18 FDG Uptake in Metastatic Spindle Cell Carcinoma of the Lung. Clinical Nuclear Medicine, 2001, 26, 79-80.	1.3	2
221	Impact of attenuation correction on the accuracy of FDG-PET in patients with abdominal tumors: a free-response ROC analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1365-1371.	2.1	25
222	N-(n-benzylpiperidin-4-yl)-2-[18f]fluorobenzamide: a potential ligand for pet imaging of breast cancer. Nuclear Medicine and Biology, 2000, 27, 763-767.	0.6	18
223	Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Correlated With Computed Tomographic Scan and Magnetic Resonance Imaging in a Case of Hematometrocolpos. Clinical Nuclear Medicine, 2000, 25, 486-487.	1.3	5
224	Regional Cerebral Glucose Metabolism in Healthy Volunteers Determined by Fluordeoxyglucose Positron Emission Tomography. Clinical Nuclear Medicine, 2000, 25, 596-602.	1.3	28
225	Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18f-fluoro-2-deoxy-D-glucose positron emission tomography. Laryngoscope, 1999, 109, 970-975.	2.0	105
226	Can the standardized uptake value characterize primary brain tumors on FDG-PET?. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1501-1509.	6.4	87
227	Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1345.	2.1	261
228	The Clinical Impact of FDG-PET Imaging on the Management of Lung Cancer Patients in a New Canadian PET Center. Molecular Imaging and Biology, 1999, 2, 349.	0.3	0
229	Prognostic value of FDG PET imaging in malignant pleural mesothelioma. Journal of Nuclear Medicine, 1999, 40, 1241-5.	5.0	75
230	Clinical evaluation of processing techniques for attenuation correction with 137Cs in whole-body PET imaging. Journal of Nuclear Medicine, 1999, 40, 1257-63.	5.0	22
231	A comparison of segmentation and emission subtraction for singles transmission in PET. IEEE Transactions on Nuclear Science, 1998, 45, 1212-1218.	2.0	24
232	Metabolic Imaging of Malignant Pleural Mesothelioma With Fluorodeoxyglucose Positron Emission Tomography. Chest, 1998, 114, 713-722.	0.8	237
233	Detection of Unsuspected Recurrent Lymphoma With Fluorodeoxyglucose-Positron Emission Tomographic Imaging After Induction Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 1998, 21, 126-128.	1.3	7
234	FDG-PET IMAGING: AN AID TO THE CLINICIAN IN THE MANAGEMENT OF PAINFUL HIP PROSTHESES.. Clinical Nuclear Medicine, 1998, 23, 791.	1.3	0

#	Article	IF	Citations
235	Whole-body positron emission tomography for oncology imaging using singles transmission scanning with segmentation and ordered subsets-expectation maximization (OS-EM) reconstruction. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 659-61.	2.1	18
236	Singles transmission scans performed post-injection for quantitative whole body PET imaging. IEEE Transactions on Nuclear Science, 1997, 44, 1329-1335.	2.0	48
237	N-(N-Benzylpiperidin-4-yl)-2-[18F]fluorobenzamide: A potential ligand for PET imaging of Ïƒ receptors. Nuclear Medicine and Biology, 1997, 24, 671-676.	0.6	34
238	False-positive 201thallium study in Wolff-Parkinson-White syndrome. Canadian Journal of Cardiology, 1996, 12, 499-502.	1.7	6
239	Rapid washout of technetium-99m-MIBI from a large parathyroid adenoma. Journal of Nuclear Medicine, 1995, 36, 241-3.	5.0	56
240	Tl-201 Chloride Bone Marrow Uptake in a Patient With Minor Thalassemia. Clinical Nuclear Medicine, 1994, 19, 822-823.	1.3	0
241	PHTHALOCYANINE AND NAPHTHALOCYANINE PHOTOSENSITIZED OXIDATION OF 2â€²â€DEOXYGUANOSINE. Photochemistry and Photobiology, 1992, 55, 809-814.	2.5	101
242	PHTHALOCYANINE AND NAPHTHALOCYANINE PHOTOSENSITIZED OXIDATION OF 2'-DEOXYGUANOSINE: DISTINCT TYPE I AND TYPE II PRODUCTS. Photochemistry and Photobiology, 1984, 39, 809-814.	2.5	4
243	Singles transmission scans performed post-injection for quantitative whole body FDG-PET. , 0, , .		0
244	A comparison of segmentation and emission subtraction for singles transmission in PET. , 0, , .		4
245	Determination of scatter characteristics generated from out of FOV source in FDG-PET studies. , 0, , .		2
246	Coupling of /sup 11/C-acetate and /sup 13/N-ammonia for measurement of myocardial blood flow in normal rats using the Sherbrooke PET scanner. , 0, , .		0
247	Cardiac PET imaging of blood flow, metabolism and function in normal and infarcted rats. , 0, , .		0